Duchenne and Becker muscular dystrophies (DMD/BMD) are recessively inherited X-linked neuromuscular diseases that result from abnormal expression of the protein dystrophin. A direct approach to treating or curing this disease would be to provide exogenous dystrophin to replace the absent or defective dystrophin in tissues affected by the disease. Gene therapy could be used to provide dystrophin to both muscle and brain cells via delivery of mini-gene vectors containing cloned copies of the dystrophin mRNA. This project will address the feasibility of using gene therapy to treat DMD/BMD by examining whether such an approach can be used to alleviate symptoms in the mdx mouse, an animal model for DMD. The initial goal of this research will be to determine whether dystrophin can be provided via DNAbased techniques to each affected tissue of the mdx mouse: skeletal, cardiac, and smooth muscle as well as the brain. Two approaches will be tested, both of which will utilize mini-gene expression vectors containing full-length murine dystrophin cDNA clones. In the first approach the mini-genes will be microinjected into mouse embryos to create transgenic mice. A variety of gene regulatory elements will be tested, enabling both positive and negative effects of dystrophin expression to be monitored in multiple tissue types. A second and more straightforward approach will involve direct injection of dystrophin minigenes into mdx mouse skeletal muscle. These experiments will address the possibility of delivering dystrophin to muscle without the use of viral vectors or embryo microinjections. Detailed comparisons will be made of physiological abnormalities in mdx muscle as compared with control animals. These experiments will provide the basis for an analysis of whether the exogenous dystrophin is able to assume a functional role. Current assays for effective expression are limited to morphological and immunological determinations. In addition, a variety of altered cDNA constructs will be tested to determine whether cDNA clones shortened by internal truncation are able to encode a functional dystrophin protein. Finally, scanning strategies based upon the polymerase chain reaction will be employed to identify the genetic mutation in two newer strains of mdx mice. Identification of the lesions in these animals will facilitate genetic analyses of dystrophin expression in several mutant strains. These experiments also will reveal whether such scanning methods might be applicable for routine diagnosis of cases of DMD thought to have arisen from point mutations.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR040864-03
Application #
3161327
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1991-04-01
Project End
1995-03-31
Budget Start
1993-04-01
Budget End
1994-03-31
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Park, Joshua S; Vohra, Ravneet; Klussmann, Thomas et al. (2018) Non-invasive tracking of disease progression in young dystrophic muscles using multi-parametric MRI at 14T. PLoS One 13:e0206323
Filareto, Antonio; Maguire-Nguyen, Katie; Gan, Qiang et al. (2018) Monitoring disease activity noninvasively in the mdx model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 115:7741-7746
Nelson, D'anna M; Lindsay, Angus; Judge, Luke M et al. (2018) Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins. Hum Mol Genet 27:2090-2100
Adams, Marvin E; Odom, Guy L; Kim, Min Jeong et al. (2018) Syntrophin binds directly to multiple spectrin-like repeats in dystrophin and mediates binding of nNOS to repeats 16-17. Hum Mol Genet 27:2978-2985
Pisconti, Addolorata; Banks, Glen B; Babaeijandaghi, Farshad et al. (2016) Loss of niche-satellite cell interactions in syndecan-3 null mice alters muscle progenitor cell homeostasis improving muscle regeneration. Skelet Muscle 6:34
Bengtsson, Niclas E; Seto, Jane T; Hall, John K et al. (2016) Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum Mol Genet 25:R9-17
Hollinger, Katrin; Chamberlain, Jeffrey S (2015) Viral vector-mediated gene therapies. Curr Opin Neurol 28:522-7
Ramos, Julian; Chamberlain, Jeffrey S (2015) Gene Therapy for Duchenne muscular dystrophy. Expert Opin Orphan Drugs 3:1255-1266
Arnett, Andrea Lh; Konieczny, Patryk; Ramos, Julian N et al. (2014) Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. Mol Ther Methods Clin Dev 1:
Banks, Glen B; Combs, Ariana C; Odom, Guy L et al. (2014) Muscle structure influences utrophin expression in mdx mice. PLoS Genet 10:e1004431

Showing the most recent 10 out of 46 publications